Search hospitals > Tennessee > Chattanooga
SCRI Tennessee Oncology Chattanooga
Claim this profileChattanooga, Tennessee 37404
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Tumors
56 reported clinical trials
3 medical researchers
Summary
SCRI Tennessee Oncology Chattanooga is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Lung Cancer, Cancer, Tumors and other specialties. SCRI Tennessee Oncology Chattanooga is involved with conducting 56 clinical trials across 40 conditions. There are 3 research doctors associated with this hospital, such as Edward Arrowsmith, Edward Riker Arrowsmith, MD, and Anz III Bertrand.Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
BRAF positive
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Edward ArrowsmithSCRI - Tennessee Oncology Chattanooga3 years of reported clinical research
Studies Prostate Cancer
Studies Cancer
5 reported clinical trials
13 drugs studied
Edward Riker Arrowsmith, MDTennessee Oncology Chattanooga-SCRI2 years of reported clinical research
Studies Cancer
Studies Cytochrome P450
2 reported clinical trials
3 drugs studied
Anz III BertrandTennessee Oncology, PLLC4 years of reported clinical research
Studies Follicular Lymphoma
Studies Lymphoma
1 reported clinical trial
3 drugs studied
Clinical Trials running at SCRI Tennessee Oncology Chattanooga
Breast Cancer
Follicular Lymphoma
Cancer
Ovarian Cancer
Non-Hodgkin's Lymphoma
Non-Small Cell Lung Cancer
Lymphoma
Fallopian Tube Cancer
Peritoneal Cancer
Bladder Cancer
Ovarian Suppression Therapy
for Breast Cancer
This trial tests TOL2506, a treatment that stops ovaries from working, in premenopausal women and men with hormone-sensitive breast cancer. It aims to reduce hormone levels to slow down or stop cancer growth. TOL2506 is a treatment that stops ovaries from working, similar to other ovarian suppression methods.
Recruiting2 awards Phase 39 criteria
Atezolizumab + Trastuzumab Emtansine
for Breast Cancer
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Recruiting1 award Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at SCRI Tennessee Oncology Chattanooga?
SCRI Tennessee Oncology Chattanooga is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Lung Cancer, Cancer, Tumors and other specialties. SCRI Tennessee Oncology Chattanooga is involved with conducting 56 clinical trials across 40 conditions. There are 3 research doctors associated with this hospital, such as Edward Arrowsmith, Edward Riker Arrowsmith, MD, and Anz III Bertrand.